Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Oficina francesa de transferencia de tecnología ofrece un nuevo adyuvante para mejorar la vacunación terapéutica


Oferta Tecnológica
Una oficina francesa de transferencia de tecnología ofrece un nuevo adyuvante para mejorar la vacunación terapéutica y, en particular, la respuesta inmune a las vacunas gracias a una micropartícula patentada que contiene un nuevo liposoma. La micropartícula patentada mejora la eficacia de las vacunas de ácido ribonucleico (RNA). La tecnología puede emplearse para cualquier tipo de vacuna de ácido ribonucleico en el tratamiento de tumores líquidos o sólidos, como cáncer de mama y próstata, VIH, tuberculosis, etc. La oficina ofrece asistencia técnica y jurídica y busca empresas de farmacología o biotecnología con el fin de establecer acuerdos de licencia o cooperación técnica.


A French Technology Transfer Office offers a new adujvant which improves therapeutic vaccination.
A French Technology Transfer Office (TTO) offers a new adjuvant which improves therapeutic vaccination and more precisely the vaccines´ immune response thanks to a patented micro-particle containing a new liposome.
The French TTO is looking for interested pharmacology corporates or biotechnology SMEs, either for a licensing agreement or a technical cooperation agreement.
A French TTO acting on behalf major life science research labs in Paris Region, has designed and synthetized a new patented micro-particle which strongly improves the efficacy of a type of vaccines: ribonucleic acid (RNA) vaccines.
The proof of concept has been performed on Human Papilloma Virus (HPV) inoculated to mice, but this technology can be used for any kind of RNA vaccines (for infectious diseases and oncology) to treat both liquid and solid tumours such as breast or prostate cancers, HIV, tuberculosis...

Vaccination (or active immunotherapy) consists in inserting a specific antigen linked to the pathogenic against whom the body has to be protected by stimulating the immune system.

The innovation is based on the key role of liposomal vaccination. This innovative liposome is a particle formed by lipids and mannose motif which enclosed the antigen. This liposome targets immune cells (with adjuvant effect) which allows in situ antigen production, that is the reason of its protective effect.

The partner sought could be a company interested in :
- a license agreement as the TTO is ready to negotiate directly the patents rights for specific applications, or
- a technical cooperation agreement

The French TTO is able to provide technical and legal assistance to facilitate the eventual partnership
Advantages and Innovations:
The vaccination with this technology allows a better targeting of the immune cells.
Indeed, currently the vaccines on the market are not completely efficient because the antigen is not always in contact with the immune cells due to to a specificity default.
The advantages of this new technology are:
- specifically targeting cells, dendritic cells in particular (by a optimization of activation of these cells)
- ability to facilitate antigen presentation
- protection of synthetic mRNA from its degradation
- avoiding the use of foreign DNA in cells (because RNA is used)
The vaccination with this technology improves the mouses survival of 30% compared to a classical vaccine approach
Stage of Development:
Prototype available for demonstration
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority patent application filed in 2016.
Patent Cooperation Treaty (PCT) is on progress.

Partner sought

Type and Role of Partner Sought:
The partner sought could be a company involved in the vaccination domain -not only on RNA vaccine- interested in developing some more efficient therapeutic vaccines.

A licensing agreement is open to manufacturing drugs firms which are able to drive pre-clinical testing of the new molecule, prior to its manufacturing and commercialization of the specific medicine for Papilloma Virus Human (PVH).
A technical cooperation agreement may also interest companies in biotechnology which are interested to develop new RNA vaccines.


Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Technology Keywords:
06002002 Biología celular y molecular
06002004 Ingeniería de proteínas
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos
06001006 Vacunas humanas